NCT01690143 · OUTCOME

Frequency of Grades 3 and 4 Non-hematologic Adverse Events During the Transplant Component ( 135 Days)

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation · Source last updated 2018-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

What was measured

Grading of AE's is performed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

All patients who receive transplant in the phase 1+2 of the study

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Patients Undergoing Transplantation	44

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Patients Undergoing Transplantation	22	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

denoms

description

Grading of AE's is performed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

groups

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Up to 4 1/2 months

title

Frequency of Grades 3 and 4 Non-hematologic Adverse Events During the Transplant Component ( 135 Days)

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice